TiGenix : licenses exclusive marketing and distribution rights for ChondroCelect to Sobi

TiGenix : licenses exclusive marketing and distribution rights for
ChondroCelect to Sobi

                                           Regulated information 3 April, 2014

                                                                             

TiGenix licenses exclusive marketing and distribution rights for ChondroCelect
                                   to Sobi

  oSobi to assume responsibility for the commercialisation of ChondroCelect
    in existing and new markets in Europe and beyond
  oSobi's considerable expertise and resources will enhance the availability
    of ChondroCelect to many more patients in many more countries
  oTiGenix to focus its resources on developing its pipeline of allogeneic
    treatments using expanded adipose-derived stem cells (eASC's)

LEUVEN, Belgium,  April  3, 2014  (GLOBE  NEWSWIRE) --  TiGenix  NV  (Euronext 
Brussels: TIG), the European leader in  cell therapy, announced today that  it 
has licensed the marketing and  distribution of ChondroCelect, the  cell-based 
medicinal product for  the repair  of cartilage defects  of the  knee, to  the 
international specialty healthcare company dedicated to rare diseases, Swedish
Orphan Biovitrum AB ('Sobi', NASDAQ OMX Stockholm: SOBI).

ChondroCelect was the first cell-based product to be approved in Europe. It is
currently available for  patients and reimbursed  in Belgium, the  Netherlands 
and Spain. Sales of ChondroCelect in 2013  were Euro 4.3 million, a growth  of 
25% on a like-for-like basis over 2012.

Sobi will continue to market and distribute the product where it is  currently 
available and has also acquired the  exclusive rights to expand the  product's 
availability to  patients in  multiple additional  territories, including  the 
rest of the European Union, Norway, Switzerland, Turkey, and Russia, plus  the 
countries of the Middle East and North Africa.

TiGenix will receive a royalty of 22% of the net sales of ChondroCelect in the
first year  of  the agreement,  and  20% of  the  net sales  of  ChondroCelect 
thereafter. There will be no upfront or milestone payments. The agreement will
take effect on 1 June 2014, and has a duration of 10 years.

"We are delighted to reach this agreement with Sobi", said Eduardo Bravo,  CEO 
of TiGenix.  "With  its experience  of  marketing and  distributing  specialty 
products, and with its human and financial resources, Sobi has the ability  to 
bring ChondroCelect  to  a  far  greater  number  of  patients  in  many  more 
countries. This then allows TiGenix to focus its human and financial resources
on the development of its platform and pipeline of allogeneic treatments using
expanded adipose-derived  stem  cells (eASC's)  for  the benefit  of  patients 
suffering from a range of inflammatory and immunological conditions."

"ChondroCelect is an exciting therapy, and we are proud to expand our  support 
for orthopaedic patients",  said Anders  Edvell MD,  PhD, Vice-President  Sobi 
Partner Products. "This partnership is an excellent fit with Partner Products'
strategy for  achieving sustainable  patient access  to innovative  treatments 
with a pan-European scope."

While  TiGenix  will  initially  maintain  responsibility  for  manufacturing, 
logistics and regulatory affairs, the costs of these activities will be  borne 
by Sobi. TiGenix employees currently engaged in the marketing and distribution
of ChondroCelect are expected to transfer to Sobi, thereby ensuring continuity
of know-how.

For more information

For TiGenix:
Richard Simpson
Senior Consultant, Comfi sprl
T: +32 494 578 278
richard@comfi.be

For Sobi:
Oskar Bosson
Head of Communications
T:            +46            70             410            71             80 

oskar.bosson@sobi.com

Jörgen Winroth
Head of Investor Relations
T: +1 347-224-0819, +46 8 697 2135
jorgen.winroth@sobi.com

About ChondroCelect

ChondroCelect, indicated  for cartilage  repair  in the  knee, was  the  first 
approved cell-based product in Europe  that successfully completed the  entire 
development track  from  research  through clinical  development  to  European 
approval through the centralised  procedure. ChondroCelect received  Marketing 
Authorisation in October 2009 as the first Advanced Therapy Medicinal Product,
and was  approved  for reimbursement  in  Belgium  in February  2011,  in  the 
Netherlands in June 2012 (retroactively to January 2011) and in Spain in March
2013. In addition to  these three countries,  ChondroCelect is also  currently 
being commercialised in the UK through TiGenix's commercial team as well as in
Finland through the Finnish Red Cross Blood Services with which TiGenix has  a 
distribution agreement.  A further  distribution agreement  is in  place  with 
Genpharm for the Middle-East region.

ChondroCelect  is  a  cell-based  medicinal  product  for  use  in  autologous 
chondrocyte implantation in which cells are taken from the patient's own knee,
multiplied to reach a large quantity, and then re-implanted at the site of the
defect. ChondroCelect  is  indicated  for the  repair  of  single  symptomatic 
cartilage defects of the femoral condyle of the knee (International  Cartilage 
Repair Society grades III or IV) in adults.

Treatment with ChondroCelect comprises a  two-step surgical procedure. In  the 
first step,  a  cartilage biopsy  is  obtained arthroscopically  from  healthy 
articular cartilage from a lesser-weight  bearing area of the patient's  knee. 
Chondrocytes are  isolated  from  the  biopsy, expanded  in  vitro  through  a 
process based on  cell characterisation,  and delivered as  a suspension  for 
implantation in the same  patient. ChondroCelect can  be delivered nine  weeks 
from the day of biopsy.

About Sobi

Sobi is  an  international  specialty healthcare  company  dedicated  to  rare 
diseases. Its  mission is  to  develop and  deliver innovative  therapies  and 
services to improve the lives of patients. The product portfolio is  primarily 
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and  neonatology. Sobi also markets  a 
portfolio of specialty and rare  disease products for partner companies.  Sobi 
is a  pioneer  in  biotechnology  with  world-class  capabilities  in  protein 
biochemistry and biologics manufacturing. In 2013, Sobi had total revenues  of 
SEK 2.2 billion (€253 million) and about 550 employees. The share (STO:  SOBI) 
is  listed  on  NASDAQ  OMX  Stockholm.  More  information  is  available   at 
www.sobi.com.

About TiGenix

TiGenix NV  (Euronext  Brussels:  TIG)is  a  leading  European  cell  therapy 
companywith a marketed  product for cartilage  repair, ChondroCelect®, and  a 
pipeline of  clinical  stage  allogeneic adultstem  cell  programmesfor  the 
treatment ofautoimmune and inflammatory diseases.TiGenixis based in  Leuven 
(Belgium)  and   has  operations   in  Madrid   (Spain),  and   Sittard-Geleen 
(theNetherlands). For more information please visit www.tigenix.com .

Forward-looking information

This document  may  contain  forward-looking  statements  and  estimates  with 
respect to the  anticipated future performance  of TiGenix and  the market  in 
which it operates. Certain of these statements, forecasts and estimates can be
recognised by  the  use of  words  such as,  without  limitation,  "believes", 
"anticipates", "expects",  "intends",  "plans", "seeks",  "estimates",  "may", 
"will" and "continue" and similar  expressions. They include all matters  that 
are not historical facts. Such  statements, forecasts and estimates are  based 
on  various  assumptions   and  assessments  of   known  and  unknown   risks, 
uncertainties and other factors,  which were deemed  reasonable when made  but 
may or may not prove to be correct. Actual events are difficult to predict and
may depend  upon factors  that are  beyond the  Company's control.  Therefore, 
actual results,  the  financial  condition,  performance  or  achievements  of 
TiGenix, or industry results, may turn out to be materially different from any
future results,  performance  or achievements  expressed  or implied  by  such 
statements,  forecasts   and   estimates.  Given   these   uncertainties,   no 
representations  are   made  as   to  the   accuracy  or   fairness  of   such 
forward-looking   statements,    forecasts   and    estimates.    Furthermore, 
forward-looking statements, forecasts and estimates only speak as of the  date 
of the  publication of  this  document. TiGenix  disclaims any  obligation  to 
update any such  forward-looking statement, forecast  or estimates to  reflect 
any change in the Company's expectations with regard thereto, or any change in
events, conditions or circumstances on  which any such statement, forecast  or 
estimate is based, except to the extent required by Belgian law.

HUG#1773704
 
Press spacebar to pause and continue. Press esc to stop.